EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting RHAMM in Cancer: Crosstalk with Non-Coding RNAs and Emerging Therapeutic Strategies Including Peptides, Oligomers, Antibodies, and Vaccines

Dong Oh Moon

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157198 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dong Oh Moon. Beteiligte Einrichtung: Department of Biology Education, Daegu University, 201, Daegudae-ro, Gyeongsan-si 38453, Gyeongsangbuk-do, Republic of Korea. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines, Peptides, Hyaluronan Receptors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a major cause of mortality worldwide, driven by complex molecular mechanisms that promote metastasis and resistance to therapy. Receptor for hyaluronan-mediated motility (RHAMM) has emerged as a multifunctional regulator in cancer, contributing to cell motility, invasion, proliferation, and fibrosis. In addition to being regulated by non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, and circRNAs, RHAMM serves as a promising therapeutic target. Recent developments in RHAMM-targeted strategies include function-blocking peptides (e.g., NPI-110, NPI-106, and P15-1), hyaluronan (HA) oligomers, and anti-RHAMM antibodies, all shown to modulate tumor stroma and suppress tumor invasiveness. Importantly, RHAMM-targeted peptide vaccines, such as the RHAMM-R3 epitope, have demonstrated immunogenicity and anti-leukemia efficacy in both pre-clinical and early clinical studies, suggesting their potential to elicit specific CD8+ T-cell responses and enhance graft-versus-leukemia effects. This review summarizes the intricate roles of RHAMM in cancer progression, its modulation by ncRNAs, and the translational promise of novel RHAMM-targeting approaches, providing insights into future directions for precision cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCancer VaccinesPeptidesHyaluronan ReceptorsExtracellular Matrix ProteinsRNA, UntranslatedHumansAnimalsAntibodies

Stichwörter der Autor:innen

HA oligomersRHAMMantibodiesnon-coding RNAspeptide inhibitorspeptide vaccines

Substanzen

hyaluronan-mediated motility receptorCancer VaccinesPeptidesHyaluronan ReceptorsExtracellular Matrix ProteinsRNA, UntranslatedAntibodies

Autor:innen und Institutionen

  • Department of Biology Education, Daegu University, 201, Daegudae-ro, Gyeongsan-si 38453, Gyeongsangbuk-do, Republic of Korea.

Zitieren

APA

Moon, D. O. (2025). Targeting RHAMM in Cancer: Crosstalk with Non-Coding RNAs and Emerging Therapeutic Strategies Including Peptides, Oligomers, Antibodies, and Vaccines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157198

Vancouver

Moon DO. Targeting RHAMM in Cancer: Crosstalk with Non-Coding RNAs and Emerging Therapeutic Strategies Including Peptides, Oligomers, Antibodies, and Vaccines. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157198

BibTeX
@article{Moon2025,
  author = {Moon, Dong Oh},
  title = {Targeting RHAMM in Cancer: Crosstalk with Non-Coding RNAs and Emerging Therapeutic Strategies Including Peptides, Oligomers, Antibodies, and Vaccines},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157198}
}
Kostenlos starten →